Sanofi SA
Company Profile
Business description
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, over-the-counter treatments and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 20% of total sales, but profits are shared with Regeneron. Just over 40% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Contact
46, avenue de la Great Army
Paris75017
FRAT: +33 153774000
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2024
Employees
87,994
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 8,444.50 | 70.70 | -0.83% |
CAC 40 | 7,226.98 | 199.90 | -2.69% |
DAX 40 | 19,033.64 | 414.96 | -2.13% |
Dow JONES (US) | 43,910.98 | 382.15 | -0.86% |
FTSE 100 | 8,025.77 | 99.42 | -1.22% |
HKSE | 19,653.59 | 193.29 | -0.97% |
NASDAQ | 19,281.40 | 17.36 | -0.09% |
Nikkei 225 | 38,795.28 | 580.81 | -1.48% |
NZX 50 Index | 12,674.49 | 74.87 | -0.59% |
S&P 500 | 5,983.99 | 17.36 | -0.29% |
S&P/ASX 200 | 8,187.00 | 68.60 | -0.83% |
SSE Composite Index | 3,416.40 | 5.57 | -0.16% |